Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Background Scoping reviews are a relatively new approach to evidence synthesis and currently there exists little guidance regarding the decision to choose between a systematic…
Randomized clinical trials (RCTs) define the efficacy of new cancer treatments and drive changes in clinical practice. Although the role of RCTs in generating knowledge…
‎Show CGA-IGC Podcast Series, Ep Season 7 – Episode 2: Decisional regret post-prophylactic gastrectomy for Hereditary Diffuse Gastric Cancer (HDGC) – May 1, 2024
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 450+ Peer Reviewed papers,…
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
With the escalating incidence and prevalence of cancer worldwide disproportionately affecting low- and middle-income countries, there is an urgent need for the global oncology community…
We developed a method to detect plasmin-cleaved VWF (cVWF) in plasma.cVWF forms during attacks of microthrombosis in a mouse model of thrombotic thrombocyt
Nature Communications – How cells adapt to glucose starvation is still elusive. Here, Levy et al. show that the mTOR substrate 4EBP1 protects human, mouse,…
View the current volume of the ASCO Educational Book
Journal of Neuro-Oncology – Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains…